Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death that often goes undetected in the general population. HCM is also prevalent in patients with cardio-facio-cutaneous syndrome (CFCS), which is a genetic disorder characterized by aberrant signaling in the RAS/MAPK signaling cascade. Understanding the mechanisms of HCM development in such RASopathies may lead to novel therapeutic strategies, but relevant experimental models of the human condition are lacking. Therefore, the objective of this study was to develop the first 3D human engineered cardiac tissue (hECT) model of HCM. The hECTs were created using human cardiomyocytes obtained by directed differentiation of induced pluripotent stem cells derived from a patient with CFCS due to an activating BRAF mutation. The mutant myocytes were directly conjugated at a 3:1 ratio with a stromal cell population to create a tissue of defined composition. Compared to healthy patient control hECTs, BRAF-hECTs displayed a hypertrophic phenotype by culture day 6, with significantly increased tissue size, twitch force, and atrial natriuretic peptide (ANP) gene expression. Twitch characteristics reflected increased contraction and relaxation rates and shorter twitch duration in BRAF-hECTs, which also had a significantly higher maximum capture rate and lower excitation threshold during electrical pacing, consistent with a more arrhythmogenic substrate. By culture day 11, twitch force was no longer different between BRAF and wild-type hECTs, revealing a temporal aspect of disease modeling with tissue engineering. Principal component analysis identified diastolic force as a key factor that changed from day 6 to day 11, supported by a higher passive stiffness in day 11 BRAF-hECTs. In summary, human engineered cardiac tissues created from BRAF mutant cells recapitulated, for the first time, key aspects of the HCM phenotype, offering a new in vitro model for studying intrinsic mechanisms and screening new therapeutic approaches for this lethal form of heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast to prior cardiac disease modeling approaches focused on genetic mutations, 20,42,43 this study demonstrates the use of biologics for induction of disease without requiring patient-specific human induced pluripotent stem cells.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdi, H., & Williams, L. J. (2010) · WIREs Computational Statistics · doi:10.1002/wics.101 · Cited by 11,104
What is principal component analysis?
Ringnér, M. (2008) · Nature Biotechnology · doi:10.1038/nbt0308-303 · Cited by 2,407
Biowire: a platform for maturation of human pluripotent stem cell–derived cardiomyocytes
Nunes, S. S., Miklas, J. W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2524 · Cited by 952
Rauen, K. A. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153523 · Cited by 879 · cited 3×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
BackgroundWang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
Bueno, O. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.23.6341 · Cited by 774
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Wilkins, B. J., Dai, Y.-S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., Jones, F., Kimball, T. R., & Molkentin, J. D. (2004) · Circulation Research · doi:10.1161/01.res.0000109415.17511.18 · Cited by 761 · cited 1×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
BackgroundMummery, C. L., Zhang, J., Ng, E. S., Elliott, D. A., Elefanty, A. G., & Kamp, T. J. (2012) · Circulation Research · doi:10.1161/circresaha.110.227512 · Cited by 713
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690 · cited 6×
“Recently, cardiac myocytes were derived from the induced pluripotent stem cells (iPSCs) of a patient with Noonan syndrome with multiple lentigines (formerly, LEOPARD syndrome) and found to be intrinsically hypertrophic [8].”
BackgroundMethodResultInfluentialSelf-citationGrowth of engineered human myocardium with mechanical loading and vascular coculture
Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Hauch, K. D., Pabon, L., Reinecke, H., & Murry, C. E. (2011) · Circulation Research · doi:10.1161/circresaha.110.237206 · Cited by 666 · cited 1×
“papers have described hECTs created from human iPSCs [31,32,34,35].”
Background
Cited by
Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond
Liu, C., Oikonomopoulos, A., Sayed, N., & Wu, J. C. (2018) · Development · doi:10.1242/dev.156166 · Cited by 267
“…tissue Dilated cardiomyopathy (Hinson et al., 2015; Tiburcy et al., 2017), heart failure (Tiburcy et al., 2017), hypertrophic cardiomyopathy (Cashman et al., 2016) Organ-on-chip Barth syndrome-associated cardiomyopathy (Wang et al., 2014) Skeletal muscle Engineered tissue Muscular dystrophy…”
BackgroundGoldfracht, I., Protze, S., Shiti, A., Setter, N., Gruber, A., Shaheen, N., Nartiss, Y., Keller, G., & Gepstein, L. (2020) · Nature Communications · doi:10.1038/s41467-019-13868-x · Cited by 263
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Edouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 237
Goldfracht, I., Efraim, Y., Shinnawi, R., Kovalev, E., Huber, I., Gepstein, A., Arbel, G., Shaheen, N., Tiburcy, M., Zimmermann, W. H., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.016 · Cited by 222
Smith, A. S. T., Macadangdang, J. R., Leung, W. W., Laflamme, M. A., & Kim, D. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.002 · Cited by 169
“Reprinted with permission (Cashman et al., 2016).”
Metadata
- Authors
- Cashman, T. J., Josowitz, R., Johnson, B. V., Gelb, B. D., & Costa, K. D.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Costa, Kevin D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-01-19
- Volume
- 11
- Issue
- 1
- Pages
- e0146697
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4718533
- OpenAlex
- W2372676601
- Cited by
- 101
- References
- 43
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 13 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 13 · 2018: 8 · 2017: 6 · 2016: 3
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Heart Association (12PRE12060254)
- Icahn School of Medicine at Mount Sinai
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL113499, R01HL113499, F30HL118923, HHSN268201000045C)
- National Institute of General Medical Sciences (T32GM008553)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD075735)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- hypertrophic cardiomyopathy, BRAF mutation, cardiofaciocutaneous syndrome, RASopathies, RAS/MAPK pathway, induced pluripotent stem cells, cardiomyocyte differentiation, stromal co-culture, twitch force, atrial natriuretic peptide, arrhythmogenic substrate, passive stiffness, disease modeling, sudden cardiac death
- MeSH terms
- Cardiomyopathy, Hypertrophic, Cell Differentiation, Cells, Cultured, Humans, Mutation, Myocardial Contraction, Atrial Natriuretic Factor, Tissue Engineering, Myocytes, Cardiac, Proto-Oncogene Proteins B-raf, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1371/journal.pone.0146697
- The paper
- Cashman, T. J., Josowitz, R., Johnson, B. V., Gelb, B. D., & Costa, K. D. (2016). Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy. PLOS ONE. https://doi.org/10.1371/journal.pone.0146697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.